PTPRC and neoplasm: Expression of immune surface markers at the tumor site revealed increased levels of CD45 (pan-leukocyte marker) (Fig. 2A) and CD11b (macrophages, neutrophils, and natural killer marker) (Fig. 2B) in day 3 and 5 and TLR4 (mainly expressed by immune cells) in day 3 (Fig. 2C).